Genomic alterations impact cell cycle-related genes during prostate cancer progression

in Endocrine-Related Cancer
View More View Less
  • 1 Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA

Correspondence should be addressed to H V Heemers: heemerh@ccf.org

*(V B Venkadakrishnan is now at Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA)

Restricted access

The recent genomic characterization of patient specimens has started to reveal the landscape of somatic alterations in clinical prostate cancer (CaP) and its association with disease progression and treatment resistance. The extent to which such alterations impact hallmarks of cancer is still unclear. Here, we interrogate genomic data from thousands of clinical CaP specimens that reflect progression from treatment-naïve, to castration-recurrent, and in some cases, neuroendocrine CaP for alterations in cell cycle-associated and -regulated genes, which are central to cancer initiation and progression. We evaluate gene signatures previously curated to evaluate G1-S and G2-M phase transitions or to represent the cell cycle-dependent proteome. The resulting CaP (stage)-specific overview confirmed the presence of well-known driver alterations impacting, for instance, the genes encoding p53 and MYC, and uncovered novel previously unrecognized mutations that affect others such as the PKMYT1 and MTBP genes. The cancer dependency and drugability of representative genomically altered cell cycle determinants were verified also. Taken together, these analyses on hundreds of often less-characterized cell cycle regulators expand considerably the scope of genomic alterations associated with CaP cell proliferation and cell cycle and isolate such regulatory proteins as putative drivers of CaP treatment resistance and entirely novel therapeutic targets for CaP therapy.

 

Society for Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 262 262 205
Full Text Views 35 35 29
PDF Downloads 51 51 40
  • Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman Iet al. 2018 The long tail of oncogenic drivers in prostate cancer. Nature Genetics 50 645651. (https://doi.org/10.1038/s41588-018-0078-z)

    • Search Google Scholar
    • Export Citation
  • Ben-Salem S, Venkadakrishnan VB & Heemers HV 2021 Novel insights in cell cycle dysregulation during prostate cancer progression. Endocrine-Related Cancer 28 R141R155. (https://doi.org/10.1530/ERC-20-0517)

    • Search Google Scholar
    • Export Citation
  • Grieb BC, Gramling MW, Arrate MP, Chen X, Beauparlant SL, Haines DS, Xiao H & Eischen CM 2014 Oncogenic protein MTBP interacts with MYC to promote tumorigenesis. Cancer Research 74 35913602. (https://doi.org/10.1158/0008-5472.CAN-13-2149)

    • Search Google Scholar
    • Export Citation
  • Kasten M & Giordano A 2001 Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity. Oncogene 20 18321838. (https://doi.org/10.1038/sj.onc.1204295)

    • Search Google Scholar
    • Export Citation
  • Maxwell SA & Davis GE 2000 Differential gene expression in p53-mediated apoptosis-resistant vs. apoptosis-sensitive tumor cell lines. PNAS 97 1300913014. (https://doi.org/10.1073/pnas.230445997)

    • Search Google Scholar
    • Export Citation
  • Rasool RU, Natesan R, Deng Q, Aras S, Lal P, Sander Effron S, Mitchell-Velasquez E, Posimo JM, Carskadon S & Baca SC et al. 2019 CDK7 inhibition suppresses castration-resistant prostate cancer through MED1 inactivation. Cancer Discovery 9 15381555. (https://doi.org/10.1158/2159-8290.CD-19-0189)

    • Search Google Scholar
    • Export Citation
  • Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC & Attard G et al. 2015 Integrative clinical genomics of advanced prostate cancer. Cell 161 12151228. (https://doi.org/10.1016/j.cell.2015.05.001)

    • Search Google Scholar
    • Export Citation
  • Wang J, Wang L, Chen S, Peng H, Xiao L, Du E, Liu Y, Lin D, Wang Y & Xu Y et al. 2020 PKMYT1 is associated with prostate cancer malignancy and may serve as a therapeutic target. Gene 744 144608. (https://doi.org/10.1016/j.gene.2020.144608)

    • Search Google Scholar
    • Export Citation
  • Wang M, Li X, Zhang J, Yang Q, Chen W, Jin W, Huang YR, Yang R & Gao WQ 2017 AHNAK2 is a novel prognostic marker and oncogenic protein for clear cell renal cell carcinoma. Theranostics 7 11001113. (https://doi.org/10.7150/thno.18198)

    • Search Google Scholar
    • Export Citation
  • Zhang H, Christensen CL, Dries R, Oser MG, Deng J, Diskin B, Li F, Pan Y, Zhang X & Yin Y et al. 2020 CDK7 inhibition potentiates genome instability triggering anti-tumor immunity in small cell lung cancer. Cancer Cell 37 37 .e954.e9. (https://doi.org/10.1016/j.ccell.2019.11.003)

    • Search Google Scholar
    • Export Citation
  • Zhang QX, Gao R, Xiang J, Yuan ZY, Qian YM, Yan M, Wang ZF, Liu Q, Zhao HD & Liu CH 2017 Cell cycle protein Bora serves as a novel poor prognostic factor in multiple adenocarcinomas. Oncotarget 8 4383843852. (https://doi.org/10.18632/oncotarget.16631)

    • Search Google Scholar
    • Export Citation